Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome

Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome is an extremely rare mitochondrial disorder characterized by the combination of progressive brain disease (encephalopathy), thickening of the heart muscle (hypertrophic cardiomyopathy), and dysfunction of the kidney tubules (renal tubular disease). This condition is caused by defects in mitochondrial function, specifically related to coenzyme Q10 (CoQ10) biosynthesis. Mutations in the COQ9 gene have been identified as a cause of this syndrome, leading to primary coenzyme Q10 deficiency. The disease primarily affects three major organ systems: the central nervous system, the heart, and the kidneys. Neurological features include encephalopathy with seizures, developmental delay, and progressive neurological deterioration. Cardiac involvement manifests as hypertrophic cardiomyopathy, which can impair the heart's ability to pump blood effectively. Renal tubular dysfunction leads to abnormal loss of substances normally reabsorbed by the kidneys. Additional features may include lactic acidosis reflecting impaired mitochondrial energy metabolism. Onset is typically in the neonatal or early infantile period, and the condition follows a severe and often rapidly progressive course. Treatment is largely supportive, though supplementation with coenzyme Q10 has been attempted given the underlying biochemical defect. However, the prognosis remains poor, and the disease is often fatal in early life. Management requires a multidisciplinary approach involving neurologists, cardiologists, nephrologists, and metabolic specialists.

Common questions about Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome